

**FORM 51-102F3  
MATERIAL CHANGE REPORT**

**Item 1. Name and Address of Company**

Izotropic Corporation (the “Company”)  
15718 39A Avenue  
Surrey, BC V3Z 0L1

**Item 2. Date of Material Change**

July 21, 2018

**Item 3. News Release**

The News Release dated August 1, 2018 was disseminated by Stockwatch and Market News on August 1, 2018.

**Item 4. Summary of Material Change**

The Company announces that, effective July 21, 2018, Donald Barry Lee has resigned from his position as Chief Financial Officer. The Company announces the appointment of Jody Bellefleur as Chief Financial Officer, also effective July 21, 2018, in place of Mr. Lee.

**Item 5. Full Description of Material Change**

**5.1 Full Description of Material Change**

See attached August 1, 2018 News Release.

**5.2 Disclosure for Restructuring Transactions**

Not Applicable.

**Item 6. Reliance on subsection 7.1(2) or (3) of National Instrument 51-102**

Not Applicable.

**Item 7. Omitted Information**

None.

**Item 8. Executive Officer**

Please contact Robert Thast, Chief Executive Officer of the Company, at 604-542-9458.

**Item 9. Date of Report**

August 1, 2018

**THIS NEWS RELEASE IS NOT FOR DISTRIBUTION TO U.S. NEWSWIRE SERVICES FOR DISSEMINATION IN THE UNITED STATES**

**IZOTROPIC CORPORATION**

**IZOTROPIC CORPORATION ANNOUNCES APPOINTMENT OF NEW CHIEF FINANCIAL OFFICER**

VANCOUVER, BC – August 1, 2018 – **Izotropic Corporation** (“**Izotropic**” or the “**Company**”) (CSE: IZO) announces that, effective July 21, 2018, Donald Barry Lee has resigned from his position as Chief Financial Officer. The Company announces the appointment of Jody Bellefleur as Chief Financial Officer, also effective July 21, 2018, in place of Mr. Lee.

Ms. Jody Bellefleur is a CPA, CGA with over 25 years of experience as a corporate accountant, focusing exclusively on public companies for the last 10 years. Ms. Bellefleur is responsible for all aspects of regulatory financial reporting including the preparation of quarterly financial statements, management discussion and analysis reports, the coordination of annual audits, and government tax and regulatory reporting. Robert Thast, CEO, commented, “The Company is pleased to have attracted someone with Jody’s capabilities and experience and welcomes her to our management team.” The Company wishes to thank Mr. Lee for his service and contributions as the former CFO.

About Izotropic

The Company is engaged in the development and commercialization of next generation 3-D breast CT imaging technology for early diagnosis of breast cancer, that improves patient comfort, provides a true 360-degree view acquisition and delivers high diagnostic accuracy.

ON BEHALF OF THE BOARD

*“Robert Thast”*

---

Robert Thast

Chief Executive Officer, Director  
and Promoter

For further information, please contact:

Robert Thast  
Telephone: 604.542.9458

Email: [bthast@telus.net](mailto:bthast@telus.net)